Lee A Albacker
Overview
Explore the profile of Lee A Albacker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
3935
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin D, Quintanilha J, Danziger N, Lang L, Levitan D, Hayne C, et al.
NPJ Precis Oncol
. 2024 Sep;
8(1):204.
PMID: 39277692
Microsatellite instability high (MSI-H) and mismatch repair deficient (dMMR) tumor status have been demonstrated to predict patient response to immunotherapies. We developed and validated a next-generation sequencing (NGS)-based companion diagnostic...
2.
Telli M, Litton J, Beck J, Jones J, Andersen J, Mina L, et al.
Breast Cancer
. 2024 Jun;
31(5):886-897.
PMID: 38869771
Background: Talazoparib monotherapy in patients with germline BRCA-mutated, early-stage triple-negative breast cancer (TNBC) showed activity in the neoadjuvant setting in the phase II NEOTALA study (NCT03499353). These biomarker analyses further...
3.
Risch Z, Kaffenberger B, Chung C, Samorodnitsky E, Hoskins E, Dao T, et al.
Haematologica
. 2024 May;
109(11):3816-3820.
PMID: 38813710
No abstract available.
4.
He J, Kalinava N, Doshi P, Pavlick D, Albacker L, Ebot E, et al.
J Immunother Cancer
. 2023 Nov;
11(11).
PMID: 38035725
Background: An accumulation of somatic mutations in tumors leads to increased neoantigen levels and antitumor immune response. Tumor mutational burden (TMB) reflects the rate of somatic mutations in the tumor...
5.
Turner N, Laird A, Telli M, Rugo H, Mailliez A, Ettl J, et al.
NPJ Breast Cancer
. 2023 Oct;
9(1):81.
PMID: 37803017
These analyses explore the impact of homologous recombination repair gene mutations, including BRCA1/2 mutations and homologous recombination deficiency (HRD), on the efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib in...
6.
Sharaf R, Jin D, Grady J, Napier C, Ebot E, Frampton G, et al.
NPJ Genom Med
. 2023 Sep;
8(1):26.
PMID: 37709802
Tumor cells need to activate a telomere maintenance mechanism, enabling limitless replication. The bulk of evidence supports that sarcomas predominantly use alternative lengthening of telomeres (ALT) mechanism, commonly associated with...
7.
Haberberger J, Pegram W, Britt N, Schiavone K, Severson E, Sharaf R, et al.
Oncologist
. 2023 Aug;
29(1):e47-e58.
PMID: 37619245
The authors present a cohort of 661 young adult glioblastomas diagnosed using 2016 WHO World Health Organization Classification of Tumors of the Central Nervous System, utilizing comprehensive genomic profiling (CGP)...
8.
Pao J, Biggs M, Duncan D, Lin D, Davis R, Huang R, et al.
Sci Rep
. 2023 Mar;
13(1):4404.
PMID: 36927889
Treatment of non-small cell lung cancer is increasingly biomarker driven with multiple genomic alterations, including those in the epidermal growth factor receptor (EGFR) gene, that benefit from targeted therapies. We...
9.
Hoskins E, Samorodnitsky E, Wing M, Reeser J, Hopkins J, Murugesan K, et al.
JCO Precis Oncol
. 2023 Jan;
7:e2200300.
PMID: 36623238
Purpose: Programmed cell death protein-1 (PD-1) receptor and ligand interactions are the target of immunotherapies for more than 20 cancer types. Biomarkers that predict response to immunotherapy are microsatellite instability,...
10.
Coleman N, Marcelo K, Hopkins J, Khan N, Du R, Hong L, et al.
JCO Precis Oncol
. 2023 Jan;
7:e2200211.
PMID: 36603172
Purpose: In head and neck squamous cell carcinoma (HNSCC), mutation is a new actionable oncogene driver. We aimed to evaluate mutational variants, comutation profile, and survival outcomes of this molecularly...